
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest reported)           March 22, 2006
                                           -------------------------------------


                            Advanced Biotherapy, Inc.
                            -------------------------
             (Exact name of registrant as specified in its chapter)


         Delaware                      0-26323                    51-0402415
----------------------------        -------------           --------------------
(State or other jurisdiction         (Commission               (IRS Employer
      of incorporation)              File Number)            Identification No.)


6355 Topanga Canyon Boulevard, Suite 510                            91367
----------------------------------------                         ----------
Woodland Hills, California                                       (Zip Code)
--------------------------
(Address of principal executive offices)

Registrant's telephone number, including area code   (818) 883-6716
                                                   --------------------

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2 below):

|_|  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

|_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

|_|  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

|_|  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e- 4(c))

<PAGE>

Item 8.01.     OTHER EVENTS.

               The Registrant reported that Advanced Biotherapy, Inc. has
entered into an initial Memorandum of Understanding (MOU) with Battelle for the
development and use of monoclonal antibodies to treat humans and animals exposed
to anthrax and plague as well as autoimmune diseases, as more specifically
described in the press release filed as Exhibit 99.1.









<PAGE>

EXHIBIT

Designation                                     Description of Exhibit

99.1                                            Press Release dated 03/22/06













<PAGE>

                                   Signatures

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                        ADVANCED BIOTHERAPY, INC.
                                        (Registrant)


Date: March 22, 2006                    By: /s/ Edmond Buccellato
                                            ------------------------------------
                                            Edmond Buccellato, President and CEO







<PAGE>

                                INDEX TO EXHIBITS

Exhibit                                         Description
-------                                         -----------

99.1                                            Press Release dated 03/22/06
